Bioject
This article was originally published in The Gray Sheet
Executive Summary
Developer of needleless drug delivery systems completes $15 mil. round of equity financing, firm announces May 24. Offering included the placement of about 1.5 mil. shares at $10 each and warrants to purchase approximately 225,000 shares at $11. The Portland, Oregon-based firm will use the proceeds to scale up production to meet the needs of biotech partners Amgen and Serono, and to expand R&D efforts, including the development of a pre-filled intradermal device. Other R&D initiatives include investigation of the mmune response of certain vaccines delivered with Bioject devices. The equity round was led by Merlin Biomed Group and Pequot Cpital Management; Leerink, Swann & Co. acted as placement agent for the deal, which brings Bioject's cash position to about $28 mil
You may also be interested in...
Financings In Brief
Cooper Companies: Firm's proposed $1.2 bil. acquisition of Ocular Sciences garners required shareholder approval Nov. 16. However, closure of the transaction, originally expected by November, continues to be delayed as the Federal Trade Commission reviews additional information it requested in September to supplement the two companies' initial Aug. 6 submission of merger-related information (1"The Gray Sheet" Sept. 13, 2004, p. 24). Cooper now predicts the transaction will close during the first half of its fiscal 2005, which began Nov. 1...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.